Mylan expands cancer drug recall on particle contamination worries

Tracy Staton Sterile injectable drugs are notoriously tricky to manufacture. Mylan has found that out the hard way, and it's now expanding a recall of cancer drugs that it began ...

Sanofi and Regeneron’s would-be blockbuster clears FDA hurdle, but questions remain

Damian Garde A cholesterol-slashing treatment from Sanofi and Regeneron won over a key FDA panel, signaling a likely approval but leaving unclear just which patients should get the ...

Does brand + generic really add up? Sandoz, Actavis execs count the ways

Carly Helfand These days, companies are increasingly looking to put both branded and generic meds under one roof. And Peter Goldschmidt, the U.S. president of Novartis' Sandoz unit, ...

NIH slams the brakes on drug production after contamination scare

Damian Garde The National Institutes of Health has halted production at a plant that makes drugs for clinical trials after discovering some alarming manufacturing mishaps, a move that ...

Big data tells J&J that recent grads are more loyal than experienced hires

Eric Palmer The "people analytics team" at drugmaker Johnson & Johnson used big data analysis techniques on employees to figure out whether hiring people with experience ...

Mayo Clinic’s hometown wants to be a $6.5B biotech hub

Damian Garde Rochester, MN, home of the Mayo Clinic, is an otherwise unassuming Midwestern city, housing about 111,000 people on the Zumbro River. But the town's leaders have a ...

Merck launches Sivextro in U.K.

Eric Palmer Merck is launching Sivextro, the newly approved antibiotic it picked up in its $ 9.5 billion buyout of Cubist, in the U.K. Pharmafile reports it is the first oral treatment ...

Jury sides with Merck and its execs in gender-bias case

Tracy Staton Merck & Co. won the day in a gender discrimination suit on Tuesday, as a federal jury found that former employee Kerri Colicchio failed to prove she was discriminated ...

Novartis nixes another $600M buyout deal for Gamida Cell

John Carroll Novartis won't be pulling the trigger on a $ 600 million buyout deal for Israel's Gamida Cell after all. Elbit Imaging, the majority owner of a minority stakeholder ...
Page 3 of 3123
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS